FOR IMMEDIATE RELEASE
CONTACT: Amanda Peterson Martin
Groff North America partners with Pennsylvania college for first-of-its-kind cannabinoid major
Students will have access to products, internships to advance cannabis research, job training
RED LION, Pa. – (March 24, 2022) – As the medicinal and recreational marijuana industries continue to grow, so does the need for trained professionals. Groff North America is thrilled to announce it has partnered with York College of Pennsylvania to prepare the next generation of chemists for careers in cannabis, who can graduate with a degree in Cannabinoid Chemistry.
Groff North America is an industry leader, one of five in the nation approved to hold schedule 1 registrations for testing and research of marijuana.
“Being located in York County, Pennsylvania and so close to York College, it’s truly a huge opportunity for students, for education, for science, for training, job creation,” says Groff North America founder Dr. Steven Groff.
The Cannabinoid Chemistry program is the first of its kind in Pennsylvania and within the mid-Atlantic region. York College students will achieve a Bachelor of Science, specializing in natural production extraction, purification and analysis.
“Groff North America is internationally known for their leading work in extraction of cannabinoids from hemp and medical cannabis,” said Jessica Fautch, associate professor and chair of the Chemistry Department. “As a global leader in cannabinoid research, Groff NA will inspire and drive publication-quality collaborative research with York College faculty and students.”
Groff North America will mentor students and provide internships starting fall 2022.
ABOUT GROFF NORTH AMERICA
Groff North America is a physician-owned cannabis cultivation, extraction and formulation company based in South Central, PA. Founded by Steve Groff, M.D. and lead by Joe Grzyb, CEO, Groff NA cultivates, processes, and refines both cannabis and hemp with a commitment to provide quality, consistent, sustainable, and trusted cannabis products to businesses and researchers who are registered to handle Schedule 1 drugs. Groff NA is one of three commercially focused companies with Schedule 1 registrations from the U.S. Drug Enforcement Administration for bulk cultivation of marijuana and the only company to further possess registration for patient dose manufacturing. Groff NA also has registrations, as cannabis exporter, importer, researcher, and analytical lab. In December of 2021, aided by the collaboration and cultivation expertise of Brighterside Vertical Farms, Groff NA’s cultivation facility yielded a highly successful first harvest of high quality, medical-grade cannabis. In February 2022, Groff NA completed the first legal transfer/ buy-back transaction of domestically cultivated marijuana with the DEA, allowing Groff NA to manufacture and sell its cannabis products for federally authorized research, drug development, drug manufacturing and export. With its seed-to-shelf approach and commitment to technology and human capital, Groff NA develops products to support customers in the advancement of cannabis-based medicine.